Q (haiku): What are the top 10 most frequently mutated genes across all cancer types in the MSK-CHORD Study? ▶ read_guide { "uri": "cbioportal://mutation-frequency-guide" } ▶ list_studies { "search": "MSK-CHORD", "verbose": true } ◀ result # Mutation Frequency Analysis Guide ## IMPORTANT: Reporting Mutation Frequencies - **ALWAYS report frequencies as percentages**, not raw counts: `frequency = (altered_samples / total_profiled_samples) × 100` - For quick frequency lookups, **prefer the TCGA Pan-Cancer Atlas study first**, then offer to expand to other studies - When reporting across multiple studies, show **ranges** (e.g., "TP53 is mutated in 30–60% of samples") rather than a single average - **NEVER** sum mutation events across studies to compute an aggregate frequency — this can exceed 100% due to double-counting - Warn users that samples may overlap across cohorts (e.g., MSK studies may share patients) - **Choose and state the counting unit**: use patient-level frequencies for prevalence/rate questions unless the user explicitly asks for samples; use sample-level frequencies when the user asks about samples. - **For "across cancer types" questions**, jump to the [Cross-Cancer-Type Mutation Frequency](#cross-cancer-type-mutation-frequency) section below — there is one correct recipe and several common wrong ones. ## Counting Unit: Samples vs Patients Before answering any mutation count or frequency question, decide whether the unit is samples or patients and state that choice in the answer. | User wording | Counting unit | |--------------|---------------| | "prevalence", "rate", "fraction of patients", "patients with", "how common is" | Patient-level: `COUNT(DISTINCT patient_unique_id)` | | "samples", "specimens", "biopsies", sample-level cohort composition | Sample-level: `COUNT(DISTINCT sample_unique_id)` | | Ambiguous | Ask, or default to patient-level for prevalence/rate language and say so | ### Cross-study sample-count caveat When an answer touches more than one study and reports a sample count, prepend a one-line caveat: > Sample IDs are unique within cBioPortal study prefixes, not guaranteed biological-sample identifiers across studies; overlapping cohorts can count the same patient/sample more than once. Prefer one of these safer approaches: - Use a shipped `cancer_study_query_preferences` cohort such as `pan_cancer_tcga` or `all_studies_non_redundant`. - Restrict to one named study. - Aggregate by `patient_unique_id` when the biological question is patient prevalence. ## STOP rule: a frequency above 100% means your query is wrong If your query returns a frequency over 100%, **do not try to debug or explain the data inconsistency to the user**. The cause is always one of these query bugs: - Summing mutation events instead of `COUNT(DISTINCT sample_unique_id)` for the numerator - Using a study-wide sample count as the denominator instead of the gene-specific profiled count - Cross-study aggregation where the same biological sample appears under multiple `sample_unique_id` values (e.g., MSK-IMPACT and MSK-CHORD share patients) - **Joining the profiled CTE through `gene_panel` / `gene_panel_list` without a WES branch.** `gene_panel_id = 'WES'` is *not* a row in … (35166 more chars) ◀ result {"result":[{"cancer_study_identifier":"msk_chord_2024","name":"MSK-CHORD (MSK, Nature 2024)","description":"Targeted sequencing of 25040 tumors from 24950 patients and their matched normals via MSK-IMPACT, along with clinical annotations, some of which are derived from natural language processing (denoted NLP). This data is available under the Creative Commons BY-NC-ND 4.0 license. For commercial use, please contact datarequests@mskcc.org","type_of_cancer_id":"mixed","sample_count":25040,"has_guide":true,"url":"https://www.cbioportal.org/study/summary?id=msk_chord_2024"}]} ▶ clickhouse_run_select_query { "query": " SELECT * FROM top_mutated_genes_in_study( study = 'msk_chord_2024', top_n = 10 ) ORDER BY altered_samples DESC LIMIT 10; ", "max_rows": 10 } ◀ result {"rows":[{"hugo_gene_symbol":"TP53","altered_samples":13124,"profiled_samples":25040,"frequency_pct":52.4,"total_mutation_events":13876},{"hugo_gene_symbol":"KRAS","altered_samples":7128,"profiled_samples":25040,"frequency_pct":28.5,"total_mutation_events":7231},{"hugo_gene_symbol":"APC","altered_samples":4777,"profiled_samples":25040,"frequency_pct":19.1,"total_mutation_events":7187},{"hugo_gene_symbol":"PIK3CA","altered_samples":3708,"profiled_samples":25040,"frequency_pct":14.8,"total_mutation_events":4178},{"hugo_gene_symbol":"EGFR","altered_samples":2159,"profiled_samples":25040,"frequency_pct":8.6,"total_mutation_events":2556},{"hugo_gene_symbol":"ARID1A","altered_samples":1843,"profiled_samples":25040,"frequency_pct":7.4,"total_mutation_events":2205},{"hugo_gene_symbol":"SMAD4","altered_samples":1796,"profiled_samples":25040,"frequency_pct":7.2,"total_mutation_events":1925},{"hugo_gene_symbol":"KMT2D","altered_samples":1783,"profiled_samples":25040,"frequency_pct":7.1,"total_mutation_events":2390},{"hugo_gene_symbol":"KMT2C","altered_samples":1629,"profiled_samples":25040,"frequency_pct":6.5,"total_mutation_events":1979},{"hugo_gene_symbol":"ATM","altered_samples":1388,"profiled_samples":25040,"frequency_pct":5.5,"total_mutation_events":1681}]} ▶ resolve_and_route { "studyIds": [ "msk_chord_2024" ] } ◀ result {"success":true,"message":"Found 1 study. Use the metadata to call the appropriate navigation tool(s).","data":{"totalCount":1,"studiesWithMetadata":[{"studyId":"msk_chord_2024","name":"MSK-CHORD (MSK, Nature 2024)","sampleCount":25040,"studyViewUrl":"https://www.cbioportal.org/study?id=msk_chord_2024","metadata":{"clinicalAttributeIds":["ADRENAL_GLANDS","BONE","CANCER_TYPE","CANCER_TYPE_DETAILED","CLINICAL_GROUP","CLINICAL_SUMMARY","CNS_BRAIN","CURRENT_AGE_DEID","DIAGNOSIS_DESCRIPTION","ETHNICITY","FRACTION_GENOME_ALTERED","GENDER","GENE_PANEL","GLEASON_FIRST_REPORTED","GLEASON_HIGHEST_REPORTED","GLEASON_SAMPLE_LEVEL","HER2","HISTORY_OF_PDL1","HR","ICD_O_HISTOLOGY_DESCRIPTION","INTRA_ABDOMINAL","LIVER","LUNG","LYMPH_NODES","METASTATIC_SITE","MSI_COMMENT","MSI_SCORE","MSI_TYPE","MUTATION_COUNT","NUM_ICDO_DX","ONCOTREE_CODE","OS_MONTHS","OS_STATUS","OTHER","PATHOLOGICAL_GROUP","PDL1_POSITIVE","PLEURA","PRIMARY_SITE","PRIOR_MED_TO_MSK","RACE","REPRODUCTIVE_ORGANS","SAMPLE_CLASS","SAMPLE_COUNT","SAMPLE_COVERAGE","SAMPLE_TYPE","SMOKING_PREDICTIONS_3_CLASSES","SOMATIC_STATUS","STAGE_HIGHEST_RECORDED","TMB_NONSYNONYMOUS","TUMOR_PURITY"],"molecularProfileIds":["msk_chord_2024_cna","msk_chord_2024_mutations","msk_chord_2024_structural_variants"],"availableComparisonTabs":["overlap","clinical","survival","alterations","mutations"]}}]}} ▶ navigate_to_results_view { "studyIds": [ "msk_chord_2024" ], "genes": [ "TP53", "KRAS", "APC", "PIK3CA", "EGFR", "ARID1A", "SMAD4", "KMT2D", "KMT2C", "ATM" ], "tab": "oncoprint" } ◀ result {"success":true,"message":"Navigating to https://www.cbioportal.org/results/oncoprint?cancer_study_list=msk_chord_2024&gene_list=TP53%0AKRAS%0AAPC%0APIK3CA%0AEGFR%0AARID1A%0ASMAD4%0AKMT2D%0AKMT2C%0AATM&case_set_id=msk_chord_2024_all","url":"https://www.cbioportal.org/results/oncoprint?cancer_study_list=msk_chord_2024&gene_list=TP53%0AKRAS%0AAPC%0APIK3CA%0AEGFR%0AARID1A%0ASMAD4%0AKMT2D%0AKMT2C%0AATM&case_set_id=msk_chord_2024_all","data":{"studyIds":["msk_chord_2024"],"studies":[{"studyId":"msk_chord_2024","name":"MSK-CHORD (MSK, Nature 2024)","sampleCount":25040}],"genes":["TP53","KRAS","APC","PIK3CA","EGFR","ARID1A","SMAD4","KMT2D","KMT2C","ATM"],"caseSetId":"msk_chord_2024_all","pageDescription":"Visual summary of alterations in queried genes across samples."}} ═ answer (success) ## Top 10 Most Frequently Mutated Genes in MSK-CHORD **Study:** MSK-CHORD (25,040 samples) **Counting unit:** Sample-level mutation frequencies across all cancer types | Rank | Gene | Mutated Samples | Profiled Samples | Frequency | Mutation Events | |------|------|-----------------|------------------|-----------|-----------------| | 1 | **TP53** | 13,124 | 25,040 | **52.4%** | 13,876 | | 2 | **KRAS** | 7,128 | 25,040 | **28.5%** | 7,231 | | 3 | **APC** | 4,777 | 25,040 | **19.1%** | 7,187 | | 4 | **PIK3CA** | 3,708 | 25,040 | **14.8%** | 4,178 | | 5 | **EGFR** | 2,159 | 25,040 | **8.6%** | 2,556 | | 6 | **ARID1A** | 1,843 | 25,040 | **7.4%** | 2,205 | | 7 | **SMAD4** | 1,796 | 25,040 | **7.2%** | 1,925 | | 8 | **KMT2D** | 1,783 | 25,040 | **7.1%** | 2,390 | | 9 | **KMT2C** | 1,629 | 25,040 | **6.5%** | 1,979 | | 10 | **ATM** | 1,388 | 25,040 | **5.5%** | 1,681 | --- ### Key Findings - **TP53** is the dominant mutated gene at 52.4%, expected for a pan-cancer cohort (frequent in solid tumors across most cancer types). - **KRAS** (28.5%) and **APC** (19.1%) follow, with strong enrichment in colorectal, pancreatic, and lung cancers. - **PIK3CA** (14.8%) and **EGFR** (8.6%) show significant alteration rates, particularly in breast and lung cancers respectively. - The remaining genes (ARID1A, SMAD4, KMT2D, KMT2C, ATM) each mutated in 5.5–7.4% of samples, represent frequently altered chromatin modifiers and DNA repair genes. --- ### Explore the Data [**View OncoPrint for Top 10 Genes**](https://www.cbioportal.org/results/oncoprint?cancer_study_list=msk_chord_2024&gene_list=TP53%0AKRAS%0AAPC%0APIK3CA%0AEGFR%0AARID1A%0ASMAD4%0AKMT2D%0AKMT2C%0AATM&case_set_id=msk_chord_2024_all) — Visualize co-occurrence of mutations across the 25,040 tumor samples. Use the **Mutations** tab to view specific variant frequencies (e.g., TP53 R175H hotspot), or **Comparison** tab to analyze differences between cancer types.